

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 46

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 46

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 46

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

Latin, English, French, Spanish:

Recommended INN *Chemical name or description; Molecular formula; Graphic formula*

DCI Recommandée *Nom chimique ou description; Formule brute; Formule développée*

DCI Recomendada *Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

abrineurinum

abrineurin

N-L-methionylneurotrophic factor (human brain-derived) cyclic
(13→80),(58→109),(68→111)-tris(disulfide), dimer

abrineurine

dimère du (13→80),(58→109),(68→111)-tris(disulfure) cyclique du
L-méthionylfacteur neurotrophique cérébral humain

abrineurina

dímero del (13→80),(58→109),(68→111)-tris(disulfuro)cíclico del factor
N-L-metionilneurotrófico (derivado de cerebro humano)

$C_{587}H_{947}N_{177}O_{177}S_{10}$ (monomer)

M

HSDPARRGEL	SVCDSESEWV	TAADKKTAVD	MSGGTVTVLE
KVPVSKGQLK	QYFYETKCNP	MGYTKEGCRG	IDKRHWNSQC
RTTQSYVRAL	TMDSKKRIGW	RFIRIDTSCV	CTLTIKRGR

acidum carginum

carginic acid

N-carbamoyl-L-glutamic acid


acide carginique

acide (2*S*)-2-(carbamoylamino)pentanedioïque

ácido carginico

ácido *N*-carbamoil-L-glutámico

$C_6H_{10}N_2O_5$



acidum lidadronicum

lidadronic acid



[1-amino-3-(dimethylamino)propylidene]diphosphonic acid

acide lidadronique

acide [1-amino-3-(diméthylamino)propylidène]bisphosphonique

ácido lidadrónico

ácido[1-amino-3-(dimetilamino)propiliden]difosfónico

**agalsidasum alfa**

agalsidase alfa

human alpha-galactosidase isoenzyme A, isolated from human cell line, clone RAG 001, glycoform α

agalsidase alfa

isoenzyme A de l'alpha-galactosidase humaine (dimère), glycoforme α produit par la lignée humaine RAG 001

agalsidasa alfa

isoenzima A de la alfa-galactosidasa humana glicosilada, aislada de cultivos de células humanas RAG 001, glicoforma α 

(subunit protein moiety reduced)

LDNGLARTPT	MGWLHWERFM	CNLDCQEEP	SCISEKLFME
MAELMVSEGW	KDAGYEYLCI	DDCWMAQPD	SEGRQADPQ
RFPHGIRQLA	NYVHSKGLKL	GIYADVGNKT	CAGFPGSFGY
YDIDAQTFAD	WGVLLKFDG	CYCDLENLA	DGYKHMSLAL
*NRTGRSIVYS	CEWPLYMWPF	QKPNYTEIRQ	YCNHWRNFAD
IDDSWKSIS	ILDWTSFNQE	RIVDVAGPGG	WNDPMLVIG
NFGLSWNQV	TQMALWAIMA	APLFMSNDLR	HISPAKALL
QDKDVIAINQ	DPLGKQGYQL	RQGDNFEVWE	RPLSGLAWAV
AMINRQEIGG	PRSYTIAVAS	LGKGVACNPA	CFITQLLPVK
RKLGFYEWTS	RLRSHINPTG	TVLLQLENTM	QMSLKDLL

* glycosylation sites (asparagine)

* sites de glycosylation (asparagine)

* posiciones de glicosilación (asparagine)

agalsidasum beta

aqalsidase beta

α -galactosidase (human clone λ AG¹⁸ isoenzyme A subunit protein moiety reduced), glycoform β

agalsidase bêta

isoenzyme A de l'alpha-galactosidase humaine (dimère dont la partie protéique est codée par l'ADN de cellules λ AG¹⁸ humaines) glycoforme β produit par culture de cellules ovariennes de hamster chinois (CHO)

agalsidasa beta

isoenzima A de la α -galactosidasa, fracción proteica reducida obtenida del clon humano λ AG18, glicoforma β

C₂₀₂₉H₃₀₈₀N₅₄₄O₅₈₇S₂₇
(subunit protein moiety reduced)

LDNGLARTPT	MGWLHWERFM	CNLDCQEEP	SCISEKLFME
MAELMVSEGW	KDAGYEYLCI	DDCWMAQORD	SEGRQADPQ
RFPHGIRQLA	NYVHSGKLKL	GIYADVGKNT	CAGFPGSFGY
YDIDAQTFAD	WGVLLKFDG	CYCDSLENLA	DGYKHMSLAL
NRTGRSIVYS	CEWPLYMWPF	QKPNYTEIRQ	YCNHWRNFAD
IDDSWKSIXS	ILDWTSFNQE	RIVDVAGPGG	WNDPDMLVIG
NFGLSWNQVQ	TQMALWAIMA	APLFMSNDLR	HISPQAKALL
QDKDVIAINQ	DPLGKQGYQL	RQGDNFVWE	RPLSGLAWAV
AMINRQEIGG	PRSYTIAVAS	LGKGVACNPA	CFITQLLPVK
RKLGFEWTS	RLRSHINPTG	TVLLOLENTM	OMSLKDLL

alefaceptum

alefacept

1-92-antigen LFA-3 (human) fusion protein with human immunoglobulin G1 (hinge-C_H2-C_H3 γ 1-chain), dimer

aléfacept

dimère de la protéine de fusion entre le 1-92-LFA-3 humain et la région charnière C₁2-C₁3 de la chaîne γ 1 de l'immunoglobuline G1 humaine


alefacept

dimero de la proteína de fusión entre el 1-92-antígeno LFA-3 humano y la inmunoglobulina G1 (cadena γ 1 bisagra-C_L2-C_L3)

C₃₂₆₄ H₅₀₀₂ N₈₄₀ O₉₈₈ S₂₀

FSQQIYGVVY	GNVTFHVPSPN	VPLKEVLWKK	QKDKVAELEN
SEFRAFSSFK	NRVYLDTVSG	SLTIYNLTSS	DEDEYEMESP
NITDTMKFFL	YVDKTHTCPP	CPAPELLGGP	SVFLFPKPKK
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK
TKPREEQYNS	TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL
PAPIEKTISK	AKGQPREPQV	YTLPPSRDEL	TKNQVSLTCL
VKGFYPSDIA	VEWESNGQPE	NNYKTPPVVL	DSGDSFFLYS
KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK

alfatradiolum

alfatradiolestra-1,3,5(10)-triene-3,17 α -diolalfatradiolestra-1,3,5(10)-triène-3,17 α -diolalfatradiolestra-1,3,5(10)-trieno-3,17 α -diol

aprepitantum

aprepitant



3-[[*(2R,3S)*-3-(*p*-fluorophenyl)-2-[[*(αR)*- α -methyl-3,5-bis(trifluoromethyl)benzyl]oxy]morpholino]methyl]- Δ^3 -1,2,4-triazolin-5-one

aprépitant

5-[[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3-(4-fluorophényl)morpholin-4-yl]méthyl]-1,2-dihydro-3*H*-1,2,4-triazol-3-one

aprepitant

5-[[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi]-3-(4-fluorofenil)morfolin-4-il]metil]-1,2-dihidro-3*H*-1,2,4-triazol-3-ona



atrasentanum

atrasentan


(2*R*,3*R*,4*S*)-1-[(dibutylcarbamoyl)methyl]-2-(*p*-methoxyphenyl)-4-[3,4-(methylenedioxy)phenyl]-3-pyrrolidinecarboxylic acid

atrasentan

acide (2*R*,3*R*,4*S*)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoéthyl]-2-(4-méthoxyphényl)pyrrolidine-3-carboxylique

atrásentán

ácido (2*R*,3*R*,4*S*)-1-[(dibutilcarbamoil)metil]-2-(*p*-metoxifenil)-4-[3,4-(metilenodioxi)fenil]-3-pirrolidinacarboxílico



aviscuminum
aviscumine


toxin ML-I (mistletoe lectin I) (*Viscum album*)

aviscumine

toxine ML-I (lectine I de gui) (*Viscum album*) obtenue par génie génétique, constituée par deux chaînes peptidiques A (250 amino-acides) et B (264 amino-acides) liées entre elles par un pont disulfure

aviscumina

toxina ML-I (lectina I de muérdago) (*Viscum album*) obtenida por ingeniería genética, constituida por dos cadenas peptídicas A (250 aminoácidos) y B (264 aminoácidos) unidas entre sí por un puente disulfuro



MYERIRLRVT	HQTTGEEYFR	FITLLRDYVS	SGSFSNEIPL
LRQSTIPVSD	AQRFVLVELT	NQGGDSITAA	IDVTNLYVVA
YQAGDQSYFL	RDAPRGAETH	LFTGTTRSSL	PFNGSYPDLE
RYAGHRDQIP	LGIDQLIQSV	TALRFPGGST	RTQARSILIL
IQMISEAARF	NPILWRARQY	INSGASFLPD	VYMLELETSW
GQQSTQVQHS	TDGVFNNPIR	LAIPPGNFVT	LTNVRDVIAS
LAIMLFVCGE			
MDDVTCASE	PTVRIVGRNG	MCVDVRDDDF	RDGNQIQLWP
SKSNNDPNQL	WTIKRDGTIR	SNGSCLTTYG	YTAGVYVMIF
DCNTAVREAT	LWQIWGNGTI	INPRSNLVLA	ASSGIKGTTL
TVQTLDYTLG	QGWLAGNDTA	PREVTIYGFR	DLCMESNGGS
VWVETCVSSQ	KNQRWALYGD	GSIRPKQNQD	QCLTCGRDSV
STVINIVSCS	AGSSGQRWVF	TNEGAILNLK	NGLAMDVAQA
NPKLRRIIY	PATGKPNQMW	LPVP	

balaglitazonum

balaglitazone



(±)-5-[p-[(3,4-dihydro-3-methyl-4-oxo-2-quinazoliny) methoxy]benzyl]-2,4-thiazolidinedione

balaglitazone

(5*RS*)-5-[4-[(3-méthyl-4-oxo-3,4-dihydroquinazolin-2-yl)méthoxy]benzyl]thiazolidine-2,4-dione

balaglitazona

(±)-5-[p-[(3,4-dihidro-3-metil-4-oxo-2-quinazolinil)metoxi]bencil]-2,4-tiazolidinadiona

**bimosiamosum**

bimosiamose


[hexane-1,6-diylbis[6'-(α-D-mannopyranosyloxy)biphenyl-3',3-diyl]]diacetic acid

bimosiamose

acide [hexane-1,6-diylbis[6'-(α-D-mannopyranosyloxy)biphényle-3',3-diyl]]diacétique

bimosiamosa

ácido [hexano-1,6-diilbis[6'-(α-D-manopiranosiloxi)bifenil-3',3-diil]]diacético



brostallicinum


brostallicin

4-(2-bromoacrylamido)-*N'''*-(2-guanidinoethyl)-1,1',1'',1'''-tetramethyl-*N,4':N',4'':N'',4'''*-quater[pyrrole-2-carboxamide]

brostallicine

4-[[[4-[[[4-[[[4-(2-bromoprop-2-énoyl)amino]-1-méthyl-1*H*-pyrrol-2-yl]carbonyl]amino]-1-méthyl-1*H*-pyrrol-2-yl]carbonyl]amino]-1-méthyl-1*H*-pyrrol-2-yl]carbonyl]amino]-*N*-(2-guanidinoéthyl)-1-méthyl-1*H*-pyrrol-2-carboxamide

brostalicina

4-(2-bromoacrilamido)-*N'''*-(2-guanidinoetil)-1,1',1'',1'''-tetrametil-*N,4':N',4'':N'',4'''*-cuater[pirrol-2-carboxamida] $C_{30}H_{35}BrN_{12}O_5$ **dabigatranum**


dabigatran

N-[[2-[(*p*-amidinoanilino)methyl]-1-methyl-5-benzimidazolyl]carbonyl]-*N*-2-pyridyl-β-alanine

dabigatran

acide 3-[[[2-[[[4-(aminoiminométhyl)phényl]amino]méthyl]-1-méthyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoïque

dabigatrán

N-[[2-[(*p*-amidinoanilino)metil]-1-metil-5-benzimidazolil]carbonil]-*N*-2-piridil-β-alanina $C_{25}H_{25}N_7O_3$ 

diflomotecanum


diflomotecan

(5*R*)-5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3*H*,15*H*-oxepino[3',4':6,7]indolizino[1,2-*b*]quinoline-3,15-dione

diflomotécan

(5*R*)-5-éthyl-9,10-difluoro-5-hydroxy-1,4,5,13-tétrahydro-3*H*,15*H*-oxépino[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,15-dione

diflomotecán

(5*R*)-5-etil-9,10-difluoro-1,4,5,13-tetrahidro-5-hidroxi-3*H*,15*H*-oxepino[3',4':6,7]indolizino[1,2-*b*]quinolina-3,15-diona $C_{21}H_{16}F_2N_2O_4$ **edotreotidum**


edotreotide

N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-*D*-phenylalanyl-L-cysteinyl-L-tyrosyl-*D*-tryptophyl-L-lysyl-L-threonyl-*N*-[(1*R*,2*R*)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfide

édotréotide

(2→7)-disulfure cyclique du [*N*-[[4,7,10-tris(carboxyméthyl)-1,4,7,10-tétraazacyclododéc-1-yl]acétyl]-*D*-phénylalanil]-L-cystéinyl-L-tyrosyl-*D*-tryptophyl-L-lysyl-L-thréonyl-*N*'-[(1*R*,2*R*)-2-hydroxy-1-(hydroxyméthyl)propyl]-L-cystéinamide]

edotreotida

(2→7)-disulfuro cíclico de *N*-[[4,7,10-tris(carboximetil)-1,4,7,10-tetraazaciclododec-1-il]acetil]-*D*-fenilalanil-L-cisteinil-L-tirosil-*D*-triptofil-L-lisil-L-treonil-*N*-[(1*R*,2*R*)-2-hidroxi-1-(hidroximetil)propil]-L-cisteinamida $C_{65}H_{92}N_{14}O_{18}S_2$ 

edronocainum


edronocaine

N,1-dimethyl-2'-(*m*-propoxyphenoxy)diethylamine

édronocaïne

N-méthyl-*N*-[2-(3-propoxyphénoxy)éthyl]propan-2-amine

edronocaina

N,1-dimetil-2'-(*m*-propoxifenoxi)dietilamina $C_{15}H_{25}NO_2$ **eflucimibum**

eflucimibe


(S)-2-(dodecylthio)-4'-hydroxy-2',3',5'-trimethyl-2-phenylacetanilide

éflocimibe

(2*S*)-2-(dodécylsulfanyl)-*N*-(4-hydroxy-2,3,5-triméthylphényl)-2-phénylacétamide

eflucimiba

(S)-2-(dodeciltio)-4'-hidroxi-2',3',5'-trimetil-2-fenilacetanilida

 $C_{29}H_{43}NO_2S$ **eganoprostum**


eganoprost

methyl (Z)-7-[(1*R*,2*R*,3*R*)-2-[(1*E*,3*S*,7*R*)-3,7-dihydroxy-1-octenyl]-3-hydroxy-5-oxocyclopentyl]-5-heptenoate

éganoprost

(Z)-7-[(1*R*,2*R*,3*R*)-2-[(1*E*,3*S*,7*R*)-3,7-dihydroxyoct-1-ényl]-3-hydroxy-5-oxocyclopentyl]hept-5-énoate de méthyle

eganoprost

(Z)-7-[(1*R*,2*R*,3*R*)-2-[(1*E*,3*S*,7*R*)-3,7-dihidroxioc-1-enil]-3-hidroxi-5-oxociclopentil]hept-5-enoato de metilo $C_{21}H_{34}O_6$ 

emodepsidum

emodepside



cyclo[(*R*)-lactoyl-*N*-methyl-*L*-leucyl-(*R*)-3-(*p*-morpholinophenyl)lactoyl-*N*-methyl-*L*-leucyl-(*R*)-lactoyl-*N*-methyl-*L*-leucyl-(*R*)-3-(*p*-morpholinophenyl)lactoyl-*N*-methyl-*L*-leucyl]

émodepside

cyclo[(*R*)-2-hydroxypropanoyl-(*N*-méthyl-*L*-leucyl)-[(*R*)-3-[4-(morpholin-4-yl)phényl]-2-hydroxypropanoyl]-(*N*-méthyl-*L*-leucyl)-(*R*)-2-hydroxypropanoyl-(*N*-méthyl-*L*-leucyl)-[(*R*)-3-[4-(morpholin-4-yl)phényl]-2-hydroxypropanoyl]-(*N*-méthyl-*L*-leucyl)]

emodepsida

ciclo[(*R*)-lactoil-*N*-metil-*L*-leucil-(*R*)-3-(*p*-morfolinofenil)lactoil-*N*-metil-*L*-leucil-(*R*)-lactoil-*N*-metil-*L*-leucil-(*R*)-3-(*p*-morfolinofenil)lactoil-*N*-metil-*L*-leucil]

**erlizumabum**

erlizumab

immunoglobulin G1, anti-(human antigen CD18) (human-mouse monoclonal F(ab')₂ fragment γ1-chain), disulfide with human-mouse monoclonal light chain, dimer

erlizumab

immunoglobuline G1, anti-(antigène CD18 humain) fragment F(ab')₂ (chaîne γ1 de l'anticorps monoclonal de souris humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé

erlizumab

immunoglobulina G1, anti-(antígeno CD18 humano) fragmento F(ab')₂ (cadena γ1 del anticuerpo monoclonal humanizado de ratón), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón

ertapenemum

ertapenem


(4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[(3-carboxyphenyl)carbamoyl]-3-pyrrolidinyl]thio]-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

ertapénem

acide (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[(3-carboxyphényl)carbamoyl]pyrrolidin-3-yl]sulfanyl]-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

ertapenem

ácido (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[(3-carboxifenil)carbamoi]pirrolidin-3-il]sulfanil]-6-[(1*R*)-1-hidroxietyl]-4-metil-7-oxo-1-azabicyclo[3.2.0]hept-2-eno-2-carboxílico

$$C_{22}H_{25}N_3O_7S$$
**etoricoxibum**

etoricoxib


5-chloro-6'-methyl-3-[*p*-(methylsulfonyl)phenyl]-2,3'-bipyridine

étoricoxib

5-chloro-6'-méthyl-3-[4-(méthylsulfonyl)phényl]-2,3'-bipyridyle

etoricoxib

5-cloro-6'-metil-3-[4-(metilsulfoni)fenil]-2,3'-bipiridilo

$$C_{18}H_{15}ClN_2O_2S$$


eufauserasum


eufauserase

broad spectrum serine-protease enzyme, extracted from the Antarctic krill (*Euphausia superba*)

eufausérase

protéase à large spectre (enzyme à sérine) extraite de krill de l'Antartique (*Euphausia superba*)

eufauserasa

serin-proteasa de amplio espectro extraida del camarón antártico (*Euphausia superba*)

AVENC GPVAP

RNK

IVGGMEVTPH

AYPWQVGLFI

DDMYFCGCSI

ISDEWVLTAH

CMDGAGFVEV

VMGAHSIHDE

TEATQVRATS

TDFFTHENWN

SFTLSNDLAL

IKMPAPIEFN

DVIQPVCLPT

YTDASDDFVG

ESVTLTGW GK

PSDSAFGIAE

QLREVDVT TI

TTADCQAYYG

IVTDKILCID

SEGGHGSCNG

DSGGPMNYVT

GGVTQTRGIT

SFGSSTGCET

GYPDGYTRVT

SYLDWIESNT

GIAIDP

farglitazarum



farglitazar

N-(*o*-benzoylphenyl)-*O*-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-*L*-tyrosine

farglitazar

acide (2*S*)-2-[(2-benzoylphényl)amino]-3-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]phényl]propanoïque

farglitazar

ácido (2*S*)-2-[(2-benzoilfenil)amino]-3-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]fenil]propanoico

fesoterodinium


fesoterodine

2-[(1*R*)-3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate

fésotérodine

2-méthylpropanoate de 2-[(1*R*)-3-[bis(1-méthyléthyl)amino]-1-phénylpropyl]-4-(hydroxyméthyl)phényle

fesoterodina

2-metilpropanoato de 2-[(1*R*)-3-[bis(1-metiletil)amino]-1-fenilpropil]-4-(hidroximetil)fenilo $C_{26}H_{37}NO_3$ **gavilimomabum**

gavilimomab

immunoglobulin M, anti-(human antigen CD147) (mouse monoclonal ABX-CBL μ -chain), disulfide with mouse monoclonal ABX-CBL light chain, pentamer

gavilimomab

immunoglobuline M, anti-(antigène CD147 humain) (chaîne μ de l'anticorps monoclonal de souris ABX-CBL), pentamère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris ABX-CBL

gavilimomab

immunoglobulina M, anti-(antígeno CD147 humano) (cadena μ del anticuerpo monoclonal de ratón ABX-CBL), pentámero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón ABX-CBL**gemopatrilatum**


gemopatrilat

(6*S*)-hexahydro-6-[(α *S*)- α -mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-1*H*-azepine-1-acetic acid

gémopatrilate


acide [(6*S*)-2,2-diméthyl-7-oxo-6-[(2*S*)-3-phényl-2-sulfanylpropanoyl]amino]hexahydro-1*H*-azépin-1-yl]acétique

gemopatrilat


ácido [(6*S*)-2,2-dimetil-7-oxo-6-[(2*S*)-3-fenil-2-sulfanilpropanoil]amino]hexahidro-1*H*-azepin-1-il]acético $C_{19}H_{26}N_2O_4S$ 

imatinibum

imatinib	α -(4-methyl-1-piperazinyl)-3'-[[4-(3-pyridyl)-2-pyrimidinyl]amino]- <i>p</i> -tolu- <i>p</i> -toluidide
imatinib	4-[(4-méthylpipérazin-1-yl)méthyl]- <i>N</i> -[4-méthyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phényl]benzamide
imatinib	α -(4-metil-1-piperazinil)-3'-[[4-(3-piridil)-2-pirimidinil]amino]- <i>p</i> -tolu- <i>p</i> -toluidida
	$C_{29}H_{31}N_7O$

**insulinum glulisinum**

insulin glulisine	[3 ^B -L-lysine,29 ^B -L-glutamic acid]insulin (human)
insuline glulisine	[3 ^B -L-lysine,29 ^B -L-acide glutamique]insuline humaine
insulina glulisina	[3 ^B -L-lisina,29 ^B -L-ácido glutámico]insulina humana

**lemalesomabum**

lemalesomab	immunoglobulin G1, anti-(human NCA-90 granulocyte cell antigen) (mouse monoclonal IMMU-MN3 γ 1-chain), disulfide with mouse monoclonal IMMU-MN3 κ -chain, dimer
lémalésomab	immunoglobuline G1, anti-(antigène cellulaire du granulocyte humain NCA-90) (chaîne γ 1 de l'anticorps monoclonal de souris IMMU-MN3), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IMMU-MN3
lemalesomab	immunoglobulina G1, anti-(antígeno celular del granulocito humano NCA-90) (cadena γ 1 del anticuerpo monoclonal de ratón IMMU-MN3), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón IMMU-MN3

litomeglovirum

litomeglovir


2-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonamido]phenyl]carbamoyl]-2-methylpropyl glycinate

litoméglovir

aminoacétate de 3-[[4-[[[5-(diméthylamino)naphtalén-1-yl]sulfonyl]amino]phényl]amino]-2,2-diméthyl-3-oxopropyle

litomeglovir

aminoacetato de 3-[[4-[[[5-(dimetilamino)naftalen-1-il]sulfonyl]amino]fenil]amino]-2,2-dimetil-3-oxopropilo

 $C_{25}H_{30}N_4O_5S$ **micafunginum**

micafungin


(4*R*,5*R*)-4,5-dihydroxy-*N*²-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3*R*)-3-hydroxy-L-glutaminy-(3*S*,4*S*)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide

micafungine

hydrogénosulfate de 5-[(1*S*,2*S*)-2-[(2*R*,6*S*,9*S*,11*R*,12*R*,14*aS*,15*S*,16*S*,20*S*,23*S*,25*aS*)-20-[(1*R*)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tétrahydroxy-6-[(1*R*)-1-hydroxyéthyl]-16-méthyl-5,8,14,19,22,25-hexaoxo-9-[[4-[5-[4-(pentyloxy)phényl]isoxazol-3-yl]benzoyl]amino]-tétracosahydro-1*H*-dipyrrolo[2,1-*c*:2',1'-*l*][1,4,7,10,13,16]hexaazacyclohénicosén-23-yl]-1,2-dihydroxyéthyl]-2-hydroxyphényle

micafungina

hidrógenosulfato de 5-[(1*S*,2*S*)-2-[(2*R*,6*S*,9*S*,11*R*,12*R*,14*aS*,15*S*,16*S*,20*S*,23*S*,25*aS*)-20-[(1*R*)-3-amino-1-hidroxi-3-oxopropil]-2,11,12,15-tetrahidroxi-6-[(1*R*)-1-hidroxietil]-16-metil-5,8,14,19,22,25-hexaoxo-9-[[4-[5-[4-(pentiloxi)fenil]isoxazol-3-il]benzoil]amino]-tetracosahidro-1*H*-dipirrolo[2,1-*c*:2',1'-*l*][1,4,7,10,13,16]hexaazaciclohenicosén-23-il]-1,2-dihidroxietil]-2-hidroxifenilo

**mozenavirum**

mozenavir



(4*R*,5*S*,6*S*,7*R*)-1,3-bis(3-aminobenzyl)-4,7-dibenzylhexahydro-5,6-dihydroxy-2*H*-1,3-diazepin-2-one

mozénavir

(4*R*,5*S*,6*S*,7*R*)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-2*H*-1,3-diazépín-2-one

mozenavir

(4*R*,5*S*,6*S*,7*R*)-1,3-bis(3-aminobencil)-4,7-dibencil-5,6-dihidroxihexahidro-2*H*-1,3-diazepin-2-ona




navuridinum

navuridine 3'-azido-2',3'-dideoxyuridine

navuridine 1-(3-azido-2,3-didésoxy-β-D-érythro-pentofuranosyl)pyrimidine-2,4(1*H*,3*H*)-dione


navuridina 3'-azido-2',3'-didesoxiuridina

**neramexanum**

neramexane 1,3,3,5,5-pentamethylcyclohexylamine

néramexane 1,3,3,5,5-pentaméthylcyclohexanamine


neramexano 1,3,3,5,5-pentametilciclohexilamina

**nolomirolum**

nolomirole (±)-5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthylene diisobutyrate

nolomirole bis(2-méthylpropanoate) de (6*RS*)-6-(méthylamino)-5,6,7,8-tétrahydronaphtalène-1,2-diyle

nolomirol diisobutirato de (±)-5,6,7,8-tetrahidro-6-(metilamino)-1,2-naftileno

and enantiomer
et énantiomère
y enantiómero

omaciclovirum


omaciclovir

9-[(*R*)-4-hydroxy-2-(hydroxymethyl)butyl]guanine

omaciclovir

2-amino-9-[(2*R*)-4-hydroxy-2-(hydroxyméthyl)butyl]-1,9-dihydro-6*H*-purin-6-one

omaciclovir

9-[(*R*)-4-hidroxi-2-(hidroximetil)butil]guanina $C_{10}H_{15}N_5O_3$ **omalizumabum**

omalizumab

immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clone pSVIE26 γ -chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 κ -chain, dimer

omalizumab

immunoglobuline G, anti-(région Fc de l'immunoglobuline E humaine) (chaîne γ de l'anticorps monoclonal de souris E25 clone pSVIE26 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris E25 clone pSVIE26 humanisé

omalizumab

immunoglobulina G, anti-(región Fc de la inmunoglobulina E humana) (cadena γ del anticuerpo monoclonal humanizado de ratón E25 clon pSVIE26), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón E25 clon pSVIE26**peginterferonum alfa-2a**

peginterferon alfa-2a

mono(*N*²,*N*⁶-dicarboxy-L-lysyl)interferon alfa-2a, diesters with polyethylene glycol monomethyl ether

The molecular mass of the pegylated part may be indicated in the name by adding a number, for example: peginterferon alfa-2a (40KD).



peginterféron alfa-2a

interféron alfa-2a dont une des lysines en position 31, 121, 131 ou 134 est acylée par le *N*²,*N*⁶-bis[méthylpoly(oxyéthylène)oxycarbonyl]-L-lysyl
La masse molaire de la partie polyéthyléneglycol peut être indiquée dans la DCI, par exemple: peginterféron alfa-2a (40KD).

peginterferón alfa-2a

diésteres del mono (*N*², *N*⁶ -dicarboxi- L-lisil) interferón α -2a, con polietilenglicolmonometiléter

La masa molecular de la parte pegilada, si es necesario, puede indicarse en el nombre añadiendo un número, por ejemplo: peginterferón alfa-2a (40KD).



peginterferonum alfa-2b

peginterferon alfa-2b

monocarboxyinterferon alfa-2b, diesters with polyethylene glycol monomethyl ether

The molecular mass of the pegylated part may be indicated in the name by adding a number, for example: peginterferon alfa-2b (12KD).

peginterféron alfa-2b



interféron alfa 2b dont un azote de la cystéine 1 ou d'une lysine 31, 121 ou 134 est engagé dans une liaison carbamate avec l'éther monométhyllique du polyéthylène glycol



La masse molaire de la partie polyéthyléneglycol peut être indiquée dans la DCI, par exemple: peginterféron alfa-2b (12KD).

peginterferón alfa-2b

diésteres del monocarboxiinterferón alfa-2b con éter monometílico de polietilenglicol

La masa molecular de la parte pegilada, si es necesario, puede indicarse en el nombre añadiendo un número, por ejemplo: peginterferón alfa-2b (12KD).



pipendoxifenumpipendoxifene 2-(*p*-hydroxyphenyl)-3-methyl-1-[*p*-(2-piperidinoethoxy)benzyl]indol-5-olpipendoxifène 2-(4-hydroxyphényl)-3-méthyl-1-[4-[2-(pipéridin-1-yl)éthoxy]benzyl]-1*H*-indol-5-olpipendoxifeno 2-(4-hidroxifenil)-3-metil-1-[4-[2-(piperidin-1-il)etoxi]bencil]-1*H*-indol-5-ol**pitrakinraum**


pitrakinra L-methionyl-[121-aspartic acid,124-aspartic acid]interleukin-4

pitrakinra L-méthionyl-[121-acide aspartique,124-acide aspartique]interleukine-4

pitrakinra L-metionil-[121-ácido aspártico,124-ácido aspártico]interleucina-4



M



pradofloxacinum


pradofloxacin

8-cyano-1-cyclopropyl-6-fluoro-7-[(4*aS*,7*aS*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

pradofloxacin

acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4*aS*,7*aS*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

pradofloxacina

ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4*aS*,7*aS*)-octahidro-6*H*-pirrolo[3,4-*b*]piridin-6-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico $C_{21}H_{21}FN_4O_3$ **reglitazarum**


reglitazar

(4*RS*)-4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione

réglitazar

(4*RS*)-4-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]benzyl]isoxazolidine-3,5-dione

reglitazar

(4*RS*)-4-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]bencil]isoxazolidina-3,5-diona $C_{22}H_{20}N_2O_5$ and enantiomer
et énantiomère
y enantiómero**rivoglitazonum**


rivoglitazone

(±)-5-[*p*-[(6-methoxy-1-methyl-2-benzimidazolyl)methoxy]benzyl]-2,4-thiazolidinedione

rivoglitazone

(5*RS*)-5-[4-[(6-méthoxy-1-méthyl-1*H*-benzimidazol-2-yl)méthoxy]=benzyl]thiazolidine-2,4-dione

rivoglitazona

(5*RS*)-5-[4-[(6-metoxi-1-metil-1*H*-bencimidazol-2-il)metoxi]bencil]tiazolidina-2,4-diona $C_{20}H_{19}N_3O_4S$ and enantiomer
et énantiomère
y enantiómero

sabiporidum



sabiporide

N-carbamimidoyl-4-[4-(1*H*-pyrrol-2-ylcarbonyl)piperazin-1-yl]-3-(trifluoromethyl)benzamide

sabiporide

N-carbamimidoyl-4-[4-(1*H*-pyrrol-2-ylcarbonyl)piperazin-1-yl]-3-(trifluorométhyl)benzamide

sabiporida

N-carbamimidoil-4-[4-(1*H*-pirrol-2-ilcarbonil)piperazin-1-il]-3-(trifluorometil)benzamida**saftinamidum**



saftinamide

(+)-(S)-2-[[*p*-[(*m*-fluorobenzyl)oxy]benzyl]amino]propionamide

saftinamide

(2*S*)-2-[[4-(3-fluorobenzoyloxy)benzyl]amino]propanamide

saftinamida

(+)-(S)-2-[[*p*-[(*m*-fluorobencil)oxi]bencil]amino]propionamida**sibenadetum**


sibenadet

4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl]benzothiazol-2(3*H*)-one

sibénadet

4-hydroxy-7-[2-[[2-[[3-(2-phényléthoxy)propyl]sulfonyl]éthyl]amino]éthyl]benzothiazol-2(3*H*)-one

sibenadet

4-hidroxi-7-[2-[[2-[[3-(2-feniletoxi)propil]sulfonyl]etil]amino]etil]benzotiazol-2(3*H*)-ona

soblidotinum

soblidotin


*N*²-(*N,N*-dimethyl-L-valyl)-*N*'-[(1*S*,2*R*)-2-methoxy-4-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*'-methyl-L-valinamide

soblidotine

(2*S*)-2-[[(2*S*)-2-(diméthylamino)-3-méthylbutanoyl]amino]-*N*-[(1*S*,2*R*)-2-méthoxy-4-[(2*S*)-2-[(1*R*,2*R*)-1-méthoxy-2-méthyl-3-oxo-3-[(2-phényléthyl)amino]propyl]pyrrolidin-1-yl]-1-[(1*S*)-1-méthylpropyl]-4-oxobutyl]-*N*,3-diméthylbutanamide

soblidotina

(2*S*)-2-[[(2*S*)-2-(dimetilamino)-3-metilbutanoyl]amino]-*N*-[(1*S*,2*R*)-2-metoxi-4-[(2*S*)-2-[(1*R*,2*R*)-1-metoxi-2-metil-3-oxo-3-[(2-feniletil)amino]propil]pirrolidin-1-il]-1-[(1*S*)-1-metilpropil]-4-oxobutyl]-*N*,3-dimetilbutanamida

 $C_{39}H_{67}N_5O_6$
**soneclosanum**


soneclosan

5-chloro-2-(*p*-chlorophenoxy)phenol

sonéclosan

5-chloro-2-(4-chlorophénoxy)phénol

soneclosán

5-cloro-2-(*p*-clorofenoxi)fenol
 $C_{12}H_8Cl_2O_2$
**sumanirolum**


sumanirole

(R)-5,6-dihydro-5-(methylamino)-4*H*-imidazo[4,5,1-*ij*]quinolin-2(1*H*)-one

sumanirole

(5*R*)-5-(méthylamino)-5,6-dihydro-4*H*-imidazo[4,5,1-*ij*]quinoléin-2(1*H*)-one

sumanirol

(5*R*)-5-(metilamino)-5,6-dihidro-4*H*-imidazo[4,5,1-*ij*]quinolin-2(1*H*)-ona
 $C_{11}H_{13}N_3O$


taplitumomabum paptoxum

taplitumomab paptox

immunoglobulin G1, anti-(human antigen CD19) (mouse monoclonal B43 γ 1-chain), disulfide with mouse monoclonal B43 κ -chain, dimer, disulfide with protein PAP (pokeweed antiviral)

taplitumomab paptox

immunoglobuline G1, anti-(antigène humain CD19) (chaîne γ 1 de l'anticorps monoclonal de souris B43), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris B43, disulfure avec la protéine antivirale extraite du phytolaque (PAP)

taplitumomab paptox

immunoglobulina G1, anti-(antígeno humano CD 19) (cadena γ 1 del anticuerpo monoclonal de ratón B43), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón B43, disulfuro con la proteína PAP (proteína antiviral de *Phytolacca americana*)

tezacitabinum

tezacitabine



2'-deoxy-2'-[(E)-fluoromethylene]cytidine

tézacitabine

4-amino-1-[(2E)-2-(fluorométhylène)-2-désoxy- β -D-érythro-pentofuranosyl]pyrimidin-2(1H)-one

tezacitabina

2'-desoxi-2'-[(E)-fluorometileno]citidina



tidembersatum


tidembersat

N-[(3*R*,4*S*)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-3,5-difluorobenzamide

tidembersat

N-[(3*R*,4*S*)-6-acétyl-3-hydroxy-2,2-diméthyl-3,4-dihydro-2*H*-1-benzopyran-4-yl]-3,5-difluorobenzamide

tidembersat

N-[(3*R*,4*S*)-6-acetil-3-hidroxi-2,2-dimetil-3,4-dihidro-2*H*-1-benzopiran-4-il]-3,5-difluorobenzamida $C_{20}H_{19}F_2NO_4$ **tilmacoxibum**

tilmacoxib


4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide

tilmacoxib

4-(4-cyclohexyl-2-méthyl-5-oxazol-5-yl)-2-fluorobenzènesulfonamide

tilmacoxib

4-(4-ciclohexil-2-metil-5-oxazolil)-2-fluorobencenosulfonamida

 $C_{16}H_{19}FN_2O_3S$ 

tipifarnibum

tipifarnib


(+)-6-[(*R*)-amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone

tipifarnib

(+)-6-[(*R*)-amino(4-chlorophényl)(1-méthyl-1*H*-imidazol-5-yl)méthyl]-4-(3-chlorophényl)-1-méthylquinoléin-2(1*H*)-one

tipifarnib

(+)-6-[(*R*)-amino(4-clorofenil)(1-metil-1*H*-imidazol-5-il)metil]-4-(3-clorofenil)-1-metilquinolina-2(1*H*)-ona

$$\text{C}_{27}\text{H}_{22}\text{Cl}_2\text{N}_4\text{O}$$
**tomeglovirum**

tomeglovir


N-[4-[[[5-(dimethylamino)-1-naphthyl]sulfonyl]amino]phenyl]-3-hydroxy-2,2-dimethylpropanamide

toméglovir

N-[4-[[[5-(diméthylamino)naphtalén-1-yl]sulfonyl]amino]phényl]-3-hydroxy-2,2-diméthylpropanamide

tomeglovir

N-[4-[[[5-(dimetilamino)naftalen-1-il]sulfonil]amino]fenil]-3-hidroxi-2,2-dimetilpropanamida


$$\text{C}_{23}\text{H}_{27}\text{N}_3\text{O}_4\text{S}$$


traxoprodilum

traxoprodil 1-[(1*S*,2*S*)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-4-ol

traxoprodil 1-[(1*S*,2*S*)-2-hydroxy-2-(4-hydroxyphényl)-1-méthyléthyl]-4-phénylpipéridin-4-ol


traxoprodil 1-[(1*S*,2*S*)-2-hidroxi-2-(4-hidroxiifenil)-1-metiletil]-4-fenilpiperidin-4-ol

**tridolgosirum**

tridolgosir (1*S*,2*R*,8*R*,8*aR*)-octahydro-1,2,8-indolizinetriol

tridolgosir (1*S*,2*R*,8*R*,8*aR*)-octahydroindolizine-1,2,8-triol


tridolgosir (1*S*,2*R*,8*R*,8*aR*)-octahidroindolizina-1,2,8-triol

**valomaciclovirum**

valomaciclovir L-valine, 4-ester with 9-[(*R*)-4-hydroxy-2-(hydroxymethyl)butyl]guanine

valomaciclovir (2*S*)-2-amino-3-méthylbutanoate de (3*R*)-3-[(2-amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)méthyl]-4-hydroxybutyle

valomaciclovir éster de L-valina con (3*R*)-3-[(2-amino-1,6-dihidro-6-oxo-9*H*-purin-9-il)metil]-4-hidroxibutilo



vatalanibum


vatalanib

1-(*p*-chloroanilino)-4-(4-pyridylmethyl)phthalazine

vatalanib

N-(4-chlorophényl)-4-(pyridin-4-ylméthyl)phtalazin-1-amine

vatalanib

1-(*p*-cloroanilino)-4-(4-piridilmetil)ftalazina $C_{20}H_{15}ClN_4$ **visilizumabum**

visilizumab

immunoglobulin G2, anti-(human antigen CD3) (human-mouse monoclonal HuM291 γ 2-chain), disulfide with human-mouse monoclonal HuM291 κ -chain, dimer

visilizumab

immunoglobuline G2, anti-(antigène CD3 humain) (chaîne γ 2 de l'anticorps monoclonal de souris HuM291 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris HuM291 humanisé

visilizumab

immunoglobulina G2, anti-(antígeno CD3 humano) (cadena γ 2 del anticuerpo monoclonal humanizado de ratón HuM291), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón HuM291**ximelagatranum**


ximelagatran

ethyl *N*-[(*R*)-cyclohexyl][[(2*S*)-2-[[4-(hydroxycarbamimidoyl)=benzyl]carbamoyl]-1-azetidiny]carbonyl]methyl]glycinate

ximélagatran

[[[(1*R*)-2-[(2*S*)-2-[[4-[amino(hydroxyimino)méthyl]benzyl]=carbamoyl]azétidin-1-yl]-1-cyclohexyl-2-oxoéthyl]amino]acétate d'éthyle

ximelagatrán

[[[(1*R*)-2-[(2*S*)-2-[[4-[amino(hidroxiimino)metil]bencil]carbamoil]azetidín-1-il]-1-ciclohexil-2-oxoetil]amino]acetato de etilo $C_{24}H_{35}N_5O_5$ 

zelandopamum

zelandopam


(-)-(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol

zélandopam

(-)-(4S)-4-(3,4-dihydroxyphényl)-1,2,3,4-tétrahydroisoquinoléine-7,8-diol

zelandopam

(-)-(S)-4-(3,4-dihidroksifenil)-1,2,3,4-tetrahydro-7,8-isoquinolinediol

 $C_{15}H_{15}NO_4$ **ziralimumabum**

ziralimumab

immunoglobulin M, anti-(human antigen CD147) (human monoclonal ABX-RB2 μ -chain), disulfide with human monoclonal ABX-RB2 light chain, pentamer

ziralimumab

immunoglobuline M, anti-(antigène CD147 humain) (chaîne μ de l'anticorps monoclonal humain ABX-RB2), pentamère du disulfure avec la chaîne légère de l'anticorps monoclonal humain ABX-RB2

ziralimumab

immunoglobulina M, anti-(antígeno CD147 humano) (cadena μ del anticuerpo monoclonal humano ABX-RB2), pentámero del disulfuro con la cadena ligera del anticuerpo monoclonal humano ABX-RB2

AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44

(WHO Drug Information, Vol. 14, No. 3, 2000)

- p. 184 **adrogolidum**
adrogolida
sustitúyase la descripción por la siguiente:
diacetato de (5aR,11bS)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo[f]tieno[2,3-c]quinolina-9,10-diilo
- p. 198 **motexafinum**
motexafina
sustitúyase la descripción por la siguiente:
9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacicloicosina-5,14-diildipropanol
- p. 205 **tanomastatum**
tanomastat
sustitúyase la descripción por la siguiente:
ácido (2S)-4-(4'-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanil)metil]butanoico
- p. 205 **tebipenemum**
tebipenem
sustitúyase la descripción por la siguiente:
2-pivalato y (4R,5S,6S)-6-[(1R)-1-hidroxietyl]-4-metil-7-oxo-3-[[1-(2-tiazolin-2-il)-3-azetidil]sulfanil]-1-azabicyclo[3.2.0]hept-2-eno-2-carboxilato de metileno

Recommended International Nonproprietary Names (Rec. INN): List 45

Dénominations communes internationales recommandées (DCI Rec.): Liste 45

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45

(WHO Drug Information, Vol. 15, No. 1, 2001)

- p. 43 **lerdelimumabum**
lerdelimumab
replace the description by the following:
immunoglobulin G4, anti-(human transforming growth factor β 2) (human monoclonal CAT-152 α 4-chain), disulfide with human monoclonal CAT-152 β -chain, dimer
- lérdelimumab
remplacer la description par la suivante:
immunoglobuline G4, anti-(facteur de croissance transformant humain β 2) (chaîne α 4 de l'anticorps monoclonal humain CAT-152), dimère du disulfure avec la chaîne β de l'anticorps monoclonal humain CAT-152
- lerdelimumab
sustituyase la descripción por la siguiente:
immunoglobulina G4, anti-(factor β 2 de crecimiento transformador humano) (cadena α 4 del anticuerpo monoclonal humano CAT-152), dímero del disulfuro con la cadena β del anticuerpo monoclonal humano CAT-152

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.